These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

551 related items for PubMed ID: 26481941

  • 1. Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.
    Gooderham M, Papp K.
    BioDrugs; 2015 Oct; 29(5):327-39. PubMed ID: 26481941
    [Abstract] [Full Text] [Related]

  • 2. Apremilast in the treatment of psoriasis and psoriatic arthritis.
    Gooderham M, Papp K.
    Skin Therapy Lett; 2015 Oct; 20(5):1-6. PubMed ID: 26382906
    [Abstract] [Full Text] [Related]

  • 3. Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.
    Bianchi L, Del Duca E, Romanelli M, Saraceno R, Chimenti S, Chiricozzi A.
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1121-8. PubMed ID: 27376729
    [Abstract] [Full Text] [Related]

  • 4. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.
    Schafer P.
    Biochem Pharmacol; 2012 Jun 15; 83(12):1583-90. PubMed ID: 22257911
    [Abstract] [Full Text] [Related]

  • 5. Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis.
    Pincelli C, Schafer PH, French LE, Augustin M, Krueger JG.
    J Drugs Dermatol; 2018 Aug 01; 17(8):835-840. PubMed ID: 30124722
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.
    Torres T, Puig L.
    Am J Clin Dermatol; 2018 Feb 01; 19(1):23-32. PubMed ID: 28597182
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Apremilast for the management of moderate to severe plaque psoriasis.
    Vangipuram R, Alikhan A.
    Expert Rev Clin Pharmacol; 2017 Apr 01; 10(4):349-360. PubMed ID: 28276777
    [Abstract] [Full Text] [Related]

  • 11. The phosphodiesterase 4 inhibitor apremilast inhibits Th1 but promotes Th17 responses induced by 6-sulfo LacNAc (slan) dendritic cells.
    Oehrl S, Prakash H, Ebling A, Trenkler N, Wölbing P, Kunze A, Döbel T, Schmitz M, Enk A, Schäkel K.
    J Dermatol Sci; 2017 Aug 01; 87(2):110-115. PubMed ID: 28499587
    [Abstract] [Full Text] [Related]

  • 12. Apremilast for the treatment of psoriatic arthritis.
    Souto A, Gómez-Reino JJ.
    Expert Rev Clin Immunol; 2015 Aug 01; 11(12):1281-90. PubMed ID: 26503917
    [Abstract] [Full Text] [Related]

  • 13. Phosphodiesterase-4 Inhibition Reduces Cutaneous Inflammation and IL-1β Expression in a Psoriasiform Mouse Model but Does Not Inhibit Inflammasome Activation.
    Meier-Schiesser B, Mellett M, Ramirez-Fort MK, Maul JT, Klug A, Winkelbeiner N, Fenini G, Schafer P, Contassot E, French LE.
    Int J Mol Sci; 2021 Nov 28; 22(23):. PubMed ID: 34884681
    [Abstract] [Full Text] [Related]

  • 14. [Phosphodiesterase 4 inhibitors in dermatology : Role in the treatment of skin diseases].
    Schmidt MF, Albuscheit N, Yazdi AS.
    Dermatologie (Heidelb); 2024 Oct 28; 75(10):791-797. PubMed ID: 39212723
    [Abstract] [Full Text] [Related]

  • 15. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
    Ohtsuki M, Okubo Y, Komine M, Imafuku S, Day RM, Chen P, Petric R, Maroli A, Nemoto O.
    J Dermatol; 2017 Aug 28; 44(8):873-884. PubMed ID: 28391657
    [Abstract] [Full Text] [Related]

  • 16. Apremilast for the treatment of psoriasis.
    Chimenti MS, Gramiccia T, Saraceno R, Bianchi L, Garofalo V, Buonomo O, Perricone R, Chimenti S, Chiricozzi A.
    Expert Opin Pharmacother; 2015 Aug 28; 16(13):2083-94. PubMed ID: 26243735
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.
    Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, Bartlett JB, Loveland MA, Gilhar A, Cheung YF, Baillie GS, Houslay MD, Man HW, Muller GW, Stirling DI.
    Br J Pharmacol; 2010 Feb 28; 159(4):842-55. PubMed ID: 20050849
    [Abstract] [Full Text] [Related]

  • 19. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
    Gottlieb AB, Matheson RT, Menter A, Leonardi CL, Day RM, Hu C, Schafer PH, Krueger JG.
    J Drugs Dermatol; 2013 Aug 28; 12(8):888-97. PubMed ID: 23986162
    [Abstract] [Full Text] [Related]

  • 20. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Keating GM.
    Drugs; 2017 Mar 28; 77(4):459-472. PubMed ID: 28213862
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.